Skip to main content
TGTX
NASDAQ Life Sciences

Subcutaneous BRIUMVI Shows Positive Phase 1 Data, Could Double Market Opportunity for TG Therapeutics

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$36.95
Mkt Cap
$5.609B
52W Low
$25.28
52W High
$44.65
52W Position info
46% above low
Off High info
17% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

TGTX sits 46% above its 52-week low of $25.28.

Summary

TG Therapeutics reported positive Phase 1 results for a subcutaneous formulation of its key multiple sclerosis drug, BRIUMVI. The data demonstrated favorable pharmacokinetics, pharmacodynamics, and a well-tolerated safety profile, supporting a quarterly dosing regimen. This follows the completion of enrollment for the Phase 3 trial of this formulation in April, and an 8-K filing today confirming these results. Management believes a self-administered, at-home, quarterly subcutaneous option could nearly double BRIUMVI's addressable market. Top-line Phase 3 data is anticipated by year-end 2026 or early 2027, with potential approval in 2028.

At the time of this announcement, TGTX was trading at $36.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $25.28 to $44.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

TGTX - Latest Insights

TGTX
Nov 16, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $63.54
Real-time Price: $65.26 info
Change: +$1.72 (+3%) info
Market Cap: $9.803B info
TGTX
Nov 09, 2026, 4:33 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $63.55
Real-time Price: $65.26 info
Change: +$1.71 (+3%) info
Market Cap: $9.803B info
TGTX
Nov 09, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.00
Real-time Price: $65.26 info
Change: +$2.26 (+4%) info
Market Cap: $9.803B info
TGTX
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $58.11
Real-time Price: $65.26 info
Change: +$7.15 (+12%) info
Market Cap: $9.803B info
TGTX
Oct 23, 2026, 11:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $52.44
Real-time Price: $65.26 info
Change: +$12.83 (+24%) info
Market Cap: $9.803B info